FLT3 and acute myeloid leukemia: Meanwhile, we further confirmed the results of previous retrospective and prospective studies,9,14,16,20,31,32 in which sorafenib pre- or post-transplantation both could improve survival in patients with FLT3-ITD AML without increasing the risk of GVHD, especially sorafenib maintenance post-transplantation.